ArticleKidney3602026
The Relationship of Osmolality and Kidney Outcomes in Patients with Autosomal Dominant Polycystic Kidney Disease.
Article in Kidney360, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
Abstract
key pointsThe causal relationship between serum osmolality and kidney outcome remained unclear in patients with autosomal dominant polycystic kidney disease. Serum osmolality may be a possible surrogate marker for the clinical monitoring of autosomal dominant polycystic kidney disease patients, especially when access to copeptin level is limited. High serum osmolality conveys possible detrimental effect on the kidney outcomes.
backgroundCurrent treatment of autosomal dominant polycystic kidney disease (ADPKD) is mainly focused on inhibiting cystogenesis through arginine vasopressin suppression, and there has been interest in achieving similar vasopressin suppression by reduction of osmolality with increased water intake. However, the causal relationship between serum osmolality (sOSM) and kidney outcome remained unclear in patients with ADPKD. We aim to evaluate the relationship of sOSM and its effect on kidney outcome in patients with ADPKD.
methodsThree hundred and eleven tolvaptan treatment-naïve patients with ADPKD were recruited prospectively from the CysticHK cohort, a territory-wide ADPKD registry across 12 tertiary hospitals in Hong Kong. Beside clinical data, serial measurement of serum, and urinary osmolality were obtained every 6 months over 5 years. All participants were treated according to the standard of clinical care. The primary outcome was the 40% decline from baseline eGFR.
resultsPatients with a high sOSM have a worse kidney outcome, as shown by the Kaplan-Meier plots (log-rank P ≤ 0.001) and the Cox regression model that showed a 5.91 times higher risk of reaching 40% eGFR decline compared with the top with bottom quartiles of osmolality ( P = 0.018). By contrast, there is an inverse relationship for urine osmolality. A receiver-operating characteristic analysis to assess the predictive efficacy of osmolality for identifying those at high risk of kidney decline also showed a good performance for sOSM (area under the curve, 0.81; 95% confidence interval, 0.73 to 0.89; P < 0.001). The urinary osmolality did not show a clinical meaningful predictive efficacy (area under the curve, 0.35; 95% confidence interval, 0.28 to 0.43; P = 0.003).
conclusionssOSM may be a possible surrogate marker for the clinical monitoring of patients with ADPKD, especially when access to copeptin level is limited; and high sOSM conveys possible detrimental effect on the kidney outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.